GlassScriptPhysician profile
Wesley C Burkett
NPI 1578919320
$3,016.42
in general payments reported to CMS, 2019-2025
35 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,339 · 2023: $37.02 · 2024: $628 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,223.69 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $221.47 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $188.83 | 2022-2025 | Jemperli |
| Caris Mpi, INC. | $170.35 | 2025 | Mi Cancer Seek |
| Eisai INC. | $155.43 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $142.44 | 2022-2025 | Imfinzi, Lynparza |
| Karyopharm Therapeutics INC. | $92.98 | 2024 | Xpovio |
| Stemline Therapeutics INC. | $55.83 | 2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $53.39 | 2024-2025 | Libtayo |
| Recordati_rare_diseases_inc. | $44.89 | 2024-2025 | Sylvant |
| Bayer Healthcare Pharmaceuticals INC. | $44.78 | 2025 | |
| Genentech USA, INC. | $44.51 | 2025 | Tecentriq |
| Janssen Biotech, INC. | $43.76 | 2025 | Darzalex, Talvey, Balversa |
| Sobi, INC | $43.32 | 2024 | |
| Coherus Oncology, INC. | $40.21 | 2024-2025 | Loqtorzi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $40.02 | 2023-2025 | |
| Beigene USA, INC. | $39.84 | 2023-2025 | Brukinsa |
| Daiichi Sankyo INC. | $34.29 | 2024-2025 | Datroway, Enhertu |
| Abbvie INC. | $32.53 | 2025 | |
| Astellas Pharma US INC | $25.86 | 2024 | Xospata |
| Myriad Genetic Laboratories, INC. | $25.34 | 2024 | Precisetumor |
| Pfizer INC. | $22.15 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.33 | 2025 | |
| Pharmacosmos Therapeutics INC. | $19.74 | 2024 | Cosela |
| Aveo Pharmaceuticals, INC. | $19.73 | 2025 | |
| Exelixis INC. | $19.02 | 2025 | Cabometyx |
| Pharmaessentia USA Corporation | $18.33 | 2024 | Besremi |
| Agios Pharmaceuticals, INC. | $17.97 | 2025 | Pyrukynd |
| Emd Serono, INC. | $17.84 | 2025 | |
| Puma Biotechnology, INC. | $17.77 | 2024 | |
| Novocure INC. | $17.50 | 2025 | Optune Lua (Novottf-200t) |
| Hologic Sales and Service, LLC | $16.21 | 2024 | Coolseal Generator |
| Fennec Pharmaceuticals, INC. | $15.96 | 2025 | Fyarro |
| Beone Medicines USA, INC. | $15.86 | 2025 | Brukinsa |
| Integra Lifesciences Corporation | $13.25 | 2024 | Integra, Omnigraft, Integra Dermal Regeneration Template |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Burkett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.